Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company targets diseases for which the unmet medical need is high, the biology for treatment is clear and for which there are typically no approved therapies treating the underlying disease. The Company's strategy, which is predicated upon time and cost-efficient drug development, allows it to pursue multiple programs in parallel with the goal of delivering safe and effective therapies to patients with the utmost urgency. Ultragenyx’s currently approved products are Crysvita, Dojolvi, Mepsevii, and Evkeeza.